Vertex Pharmaceuticals (NASDAQ:VRTX) Share Price Breaks Below 50 Day Moving Average After Insider Selling

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) shares crossed below its 50-day moving average during trading on Thursday after an insider sold shares in the company. The stock has a 50-day moving average of $522.74 and traded as low as $517.82. Vertex Pharmaceuticals shares last traded at $520.66, with a volume of 1,176,919 shares changing hands.

Specifically, Director Sangeeta N. Bhatia sold 271 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $547.86, for a total value of $148,470.06. Following the sale, the director directly owned 4,653 shares in the company, valued at $2,549,192.58. This represents a 5.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $547,860.00. Following the transaction, the director directly owned 1,109 shares of the company’s stock, valued at approximately $607,576.74. This trade represents a 47.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In related news, EVP Charles Wagner, Jr. sold 15,286 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $547.87, for a total transaction of $8,374,740.82. Following the completion of the transaction, the executive vice president directly owned 31,764 shares in the company, valued at $17,402,542.68. The trade was a 32.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Upgrades and Downgrades

VRTX has been the topic of a number of recent research reports. Stifel Nicolaus upped their target price on Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a research note on Tuesday, November 3rd. Daiwa Securities Group raised their price target on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Scotiabank raised their price target on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 3rd. Sanford C. Bernstein raised Vertex Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. Finally, Barclays boosted their price target on Vertex Pharmaceuticals from $617.00 to $626.00 and gave the stock an “overweight” rating in a report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $596.44.

Check Out Our Latest Research Report on VRTX

Vertex Pharmaceuticals Trading Down 1.1%

The business’s 50-day moving average is $522.72 and its two-hundred day moving average is $485.26. The company has a current ratio of 2.34, a quick ratio of 1.89 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $130.51 billion, a PE ratio of 31.62, a PEG ratio of 2.85 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business’s revenue was up 11.8% on a year-over-year basis. During the same period last year, the firm posted $4.80 earnings per share. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.

Institutional Trading of Vertex Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of VRTX. Stonebrook Private Inc. grew its holdings in shares of Vertex Pharmaceuticals by 18.1% during the third quarter. Stonebrook Private Inc. now owns 534 shares of the pharmaceutical company’s stock valued at $279,000 after purchasing an additional 82 shares during the last quarter. American Century Companies Inc. raised its position in shares of Vertex Pharmaceuticals by 12.7% during the 3rd quarter. American Century Companies Inc. now owns 654,555 shares of the pharmaceutical company’s stock worth $342,208,000 after purchasing an additional 73,654 shares during the period. PCM Encore LLC lifted its holdings in shares of Vertex Pharmaceuticals by 2.3% in the 3rd quarter. PCM Encore LLC now owns 2,177 shares of the pharmaceutical company’s stock worth $1,138,000 after purchasing an additional 49 shares during the last quarter. Defiance ETFs LLC lifted its holdings in shares of Vertex Pharmaceuticals by 16.5% in the 3rd quarter. Defiance ETFs LLC now owns 1,165 shares of the pharmaceutical company’s stock worth $609,000 after purchasing an additional 165 shares during the last quarter. Finally, Kestra Advisory Services LLC lifted its holdings in shares of Vertex Pharmaceuticals by 46.1% in the 3rd quarter. Kestra Advisory Services LLC now owns 22,981 shares of the pharmaceutical company’s stock worth $12,015,000 after purchasing an additional 7,249 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

See Also

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.